Neurostimulation Devices Market Regional Analysis:
North America region is likely to hold over 58.7% market share by 2035. This can be accredited to the increasing prevalence of neurological disorders and the increasing level of the geriatric population in the region. According to statistics, in 2018, approximately 20 million US citizens experience some form of neuropathy, of which approximately 15% are individuals with brain impairment in US households. Further, the market is estimated to gain high growth during the forecast period, owing to the rising use of implantable neurostimulation devices to minimize pain and increasing initiatives to innovate medical devices in the region.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of neurostimulation devices is assessed at USD 9.13 billion.
The global neurostimulation devices market size was valued at over USD 8.23 billion in 2025 and is expected to expand at a CAGR of around 12.2%, surpassing USD 26.02 billion revenue by 2035.
North America’s neurostimulation devices market dominates with a 58.7% share by 2035, driven by rising prevalence of neurological disorders, a growing geriatric population, and increasing adoption of implantable neurostimulation devices.
Key players in the market include Abbott Laboratories, Boston Scientific Corporation, Integer Holdings Corporation, Medtronic, Nevro Corp., NeuroSigma, Inc., NeuroPace, Inc., Neuronetics, Synapse Biomedical Inc., Soterix Medical, Inc.
